Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_assertion type Assertion NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_head.
- NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_assertion description "[First, they illustrate the necessity of clinically approved assays to identify FGFR1 gene amplification, which occur in approximately 5% of breast tumors and have been linked to antiestrogen resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_provenance.
- NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_assertion evidence source_evidence_literature NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_provenance.
- NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_assertion SIO_000772 22879364 NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_provenance.
- NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_assertion wasDerivedFrom befree-20140225 NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_provenance.
- NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_assertion wasGeneratedBy ECO_0000203 NP932221.RAhtzGKh7-_PIvwO7sZBe0c-keD_Csb77n37xykEDA8ds130_provenance.